Please provide your email address to receive an email when new articles are posted on . Lepodisiran greatly lowered lipoprotein(a) at 6 months and 1 year compared with placebo. A cardiovascular ...

Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepatic ...

For the first time, a drug to treat adult patients with familial chylomicronemia syndrome (FCS), a severe and rare condition that leads to extremely high levels of blood fats called triglycerides, has ...

Please provide your email address to receive an email when new articles are posted on . Investigational therapies to lower Lp(a) include antisense oligonucleotide therapies and small interfering RNA ...

(A and B) Preparation process of the self-assembly of peptide, DNR prodrug, and siRNA, along with the corresponding formulation ratios. (C) DLS detection of the particle size of PDR at different ...

Under the terms of the agreement, GSK will obtain exclusive worldwide rights to develop, manufacture, and commercialize two of Frontier Biotech's Small Interfering RNA (siRNA) pipeline products, one ...

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...

Lab data in cells has shown that siRNA has the potential to treat COVID-19 infection better than existing antivirals, according to new research from UNSW's Kirby and RNA Institutes, published today in ...

The MarketWatch News Department was not involved in the creation of this content. NANJING, China, Feb. 24, 2026 /PRNewswire/ -- Frontier Biotechnologies Inc. (hereinafter referred to as "Frontier ...

NANJING, China, Feb. 24, 2026 /PRNewswire/ -- Frontier Biotechnologies Inc. (hereinafter referred to as "Frontier Biotech" or "the Company") has entered into an exclusive licensing agreement with GSK, ...